Date:20/04	/2024	
Your Name:	Jinhui Li	
Manuscript Title:	MRI-based prognostic mod	lel for subsequent distant metastasis in patients with ipsilateral
breast tumor recu	rrence following breast-con	serving surgery
Manuscript numb	er (if known):	QİMS-23-1831-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	The state of the s
4	Consulting fees	None	

	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending	None	
	manuscript writing or educational events Payment for expert testimony Support for attending		
	educational events Payment for expert testimony Support for attending		
	Payment for expert testimony  Support for attending		
7	Support for attending .		
	Support for attending		Control of the Contro
		None .	
	meetings and/or travel		and the state of t
Viante)			
577			er de l'Aria de production de l'aria description de la company de la company de la company de la company de la La company de la company d
	Patents planned, issued or	None	
	pending		
(District or		electron N. 2 C. Entrantia de Responsa esta esta esta esta esta esta esta es	Email a l'Exploracional desponsaciones de la constant de la consta
SECTION AND DESCRIPTION	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
ALESS CAN BE AND	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
1	group, paid or unpaid	Fire the seach managers	the file makes excited a from a fire as being the file
11	Stock or stock options	None	
			and the state of t
	Receipt of equipment,	None	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	materials, drugs, medical	Markey Committee and the Anna Committee and the Anna Committee and the Anna Committee and the Anna Committee a	
	writing, gifts or other		
	services Other financial or non-	None	
HELD BURNES	financial interests	None	
	illianciai iliterests		

No conflic	t of interes	t	
The same of the second live is a second live in the second live in the second live is a second live in the second live in the second live is a second live in the second live in the second live is a second live in the second live in the second live is a second live in the second live in the second live in the second live is a second live in the s			
Jinhur	11		
011 (1000			

Please place an "X" next to the following statement to indicate your agreement:

Date:	20/04/2024	
Your Name	e: Feilin Qu	
Manuscrip	t Title: MRI-based prognostic mod	el for subsequent distant metastasis in patients with ipsilateral
breast tum	or recurrence following breast-con	serving surgery
Manuscrip	t number (if known):	QIMS-23-1831-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,	TO THE WAR THE	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	The second secon
	testimony		
and the		en e	
7	Support for attending	None	
	meetings and/or travel		
			and the second s
	and the second of the second o		to the property of the propert
8	Patents planned, issued or	None	
	pending		and the said remotioned activities and a
9.	Participation on a Data	None	and the second
	Safety Monitoring Board or		
1 ( ) ( ) ( ) ( )	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	The state of the s
		The second secon	The second of the second secon
	group, paid or unpaid		COLD TO STANDARD THE SECTION OF THE
11	Stock or stock options	Noñè	And the second s
	Stock of stock options	المن المن المن المن المن المن المن المن	
		and the second s	The state was provided a plant to the state of the state
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

	No conflict of ir	iterest	
Fe	Cilin G	کس	

Please place an "X" next to the following statement to indicate your agreement:

Date:20/04	/2024	
Your Name:	Jing Gong	
Manuscript Title:	MRI-based prognostic mod	el for subsequent distant metastasis in patients with ipsilateral
breast tumor recu	rence following breast-con	serving surgery
Manuscript numb	er (if known):	QiM\$-23-1831-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	A Control of Control o	Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
ACRES NO	lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	Application of the second of t	
		And the second s	
7	Support for attending	None	
0.1	meetings and/or travel		
8	Patents planned, issued or	None	
	pending	por latera de la compania de la comp En la compania de la	
Ofereston.			
9	Participation on a Data	None	
	Safety Monitoring Board or	average of the second sections.	
(1) P.C	Advisory Board		The state of the s
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of stock options		
			Company of the State of the Sta
12	Receipt of equipment,	None	8000 (AD 00 44) 50 Feb. (44) 502 AD 00 AD
	materials, drugs, medical		
	writing, gifts or other		Programme and the second secon
	services		
13	Other financial or non-	None	
	financial interests		
	financial interests		

No conflict of interest	
Jiny Gung	

Please place an "X" next to the following statement to indicate your agreement:

Date:	20/04/2024
<b>Your Name</b>	Shiyun Sun
Manuscript	Title: MRI-based prognostic model for subsequent distant metastasis in patients with ipsilateral
breast tumo	recurrence following breast-conserving surgery
Manuscript	number (if known): QIMS-23-1831-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

7			and the state of t
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9.	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

No conflict of interest	
Shiyun Sun	

Please place an "X" next to the following statement to indicate your agreement:

Date:20/04/202	4	
Your Name:	Yajia Gu	
Manuscript Title: MRI	-based prognostic mod	del for subsequent distant metastasis in patients with ipsilateral
breast tumor recurrent	ce following breast-co	nserving surgery
Manuscript number (II	f known):	QIMS-23-1831-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive <u>medication</u>, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

		T	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Öther financial or non- financial interests	None	

No conflict of interest	
Majia Gu	

Please place an "X" next to the following statement to indicate your agreement:

Date:	20/04/2024	
Your Name		
Manuscript	Title: MRI-based	prognostic model for subsequent distant metastasis in patients with ipsilateral
breast tum	or recurrence follow	ving breast-conserving surgery
Manuscript	number (if known	):QIMS-23-1831-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
Alfa Alfae Market	A Company of the comp		
			and the first of the first one and the first of the
8	Patents planned, issued or	None	
	pending		
	1	D. Berlin (1994) and the second of the secon	(2.1 Mills Eller 55 pillston and auditide enrichte dinapolities in 12
9.	Participation on a Data	Nône	man paper to provide the another to the property of the desire of the provided the provided to
	Safety Monitoring Board or		
	Advisory Board		The second of th
10	Leadership or fiduciary role	None	A STATE OF THE PROPERTY OF THE
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	Stock of stock options	A CONTRACTOR OF THE PROPERTY O	
12	Receipt of equipment,	None	
-	materials, drugs, medical	and the same of th	
	writing, gifts or other		
	services	A STATE OF THE STA	and the second
L3	Other financial or non-	None	
	financial interests		

principal description of the second	No conflict of interest	
	Chao You.	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	20/04/2024	all and the state of
Your Name	: Weijun Peng	
Manuscript	Title: MRI-based prognostic mod	del for subsequent distant metastasis in patients with ipsilateral
breast tumo	or recurrence following breast-cor	nserving surgery
Manuscript number (if known):		QIM\$-23-1831-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	
4	Consulting fees	None	

		And the second discount of the second	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	See Despite to the second of t

No conflict of interest	
Nei jun fleigt	

Please place an "X" next to the following statement to indicate your agreement: